ProBioGen Announces Expansion of Commercial Licenses with Emergent BioSolutions for AGE1.CR® Viral Vaccine Manufacturing Production Platform
Berlin, Germany, 17 December 2013
ProBioGen announced that it has signed an agreement with Emergent BioSolutions for a non-exclusive commercial multi-product license and option agreement under which Emergent will be granted broad access to ProBioGen’s avian AGE1.CR® cell line. Previously, ProBioGen had granted an exclusive license to Emergent for four indications and also conducted process development work for Emergent. As a result of the new agreement, ProBioGen’s relationship with Emergent is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments. Financial details were not disclosed.
Volker Sandig, Chief Scientific Officer noted: “Innovative medicines against infectious diseases are urgently needed. We are convinced that the combination of ProBioGen’s AGE1.CR® cell line for production of MVA-based vaccines together with Emergent’s product development, manufacturing and marketing expertise will yield novel preventive and therapeutic products."
About the AGE1.CR® Cell Line
AGE1.CR® is an immortalized cell line derived from primary cells of a Muscovy Duck. The cell line was created as a platform for replacing primary chicken cells for production of vaccines and hyper-attenuated viruses in chemically defined media and suspension cultures. In addition, AGE1.CR® cells are also suitable for the generation of trans-complementing helper or packaging cell lines to support efficient production of replication-restricted viral vectors. (See e.g. Biologicals. 2011 Jan;39(1):50-8 “A chemically defined production process for highly attenuated poxviruses”)
About ProBioGen – www.probiogen.de
ProBioGen is an internationally operating technology provider and Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in cell culture, process development, and GMP-manufacturing. ProBioGen, with its scientific excellence and strong intellectual property base, is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the company’s established, fee-for-service-based CHO cell and media platform, its GlymaxX® ADCC enhancement technology and its AGE1® family of animal and human designer cell lines. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994 and is located in Berlin, Germany.
Dr. Gabriele Schneider
Vice President Business Development
Phone: +49 (0)30 924 006-0